NVAX Profile
Novavax, Inc., established in 1987 and headquartered in Gaithersburg, Maryland, is a pioneering biotechnology firm specializing in the discovery, development, and commercialization of vaccines aimed at combating serious infectious diseases and fulfilling critical health needs. The company's robust pipeline features several promising vaccine candidates at various stages of clinical development.
Among its leading initiatives is NVX-CoV2373, a coronavirus vaccine currently undergoing Phase III trials in multiple global locations, alongside Phase IIb and Phase I/II trials. Additionally, Novavax is advancing NanoFlu, an innovative nanoparticle-based seasonal quadrivalent influenza vaccine, which is currently in Phase 3 clinical trials, demonstrating its commitment to addressing prevalent infectious diseases.
Another notable candidate in its portfolio is ResVax, a respiratory syncytial virus (RSV) F protein nanoparticle vaccine being developed to safeguard vulnerable populations. The company is actively pursuing Phase II clinical trials for older adults and Phase I trials for pediatric populations, underscoring its dedication to comprehensive vaccine solutions across diverse demographic groups.
In alignment with its growth strategy, Novavax has forged strategic collaborations, including a pivotal partnership with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, its COVID-19 vaccine candidate. With a commitment to scientific innovation and global health impact, Novavax continues to position itself as a key player in the biotechnology sector, striving to deliver breakthrough vaccines that protect and improve public health worldwide.
|
